mRNA-1944
Phase 1Completed 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prevention of Chikungunya Virus Infection
Conditions
Prevention of Chikungunya Virus Infection
Trial Timeline
Jan 22, 2019 → Jun 7, 2021
NCT ID
NCT03829384About mRNA-1944
mRNA-1944 is a phase 1 stage product being developed by Moderna for Prevention of Chikungunya Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03829384. Target conditions include Prevention of Chikungunya Virus Infection.
What happened to similar drugs?
5 of 20 similar drugs in Prevention of Chikungunya Virus Infection were approved
Approved (5) Terminated (0) Active (15)
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03829384 | Phase 1 | Completed |
Competing Products
20 competing products in Prevention of Chikungunya Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gam-COVID-Vac | Dr. Reddy's Laboratories | Phase 2/3 | 31 |
| edoxaban + enoxaparin sodium | Daiichi Sankyo | Phase 3 | 40 |
| Mifepristone | Eli Lilly | Phase 2 | 35 |
| EXANTA | AstraZeneca | Phase 2 | 27 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 26 |
| DAPA/MET XR + DAPA + MET XR | AstraZeneca | Phase 3 | 40 |
| Esomeprazole + Placebo | AstraZeneca | Phase 3 | 40 |
| PCV15 | Merck | Pre-clinical | 18 |
| Raltegravir | Merck | Approved | 43 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 40 |
| V501 | Merck | Phase 3 | 40 |
| Zostavax | Merck | Phase 3 | 40 |
| V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920 | Merck | Phase 3 | 40 |
| Letermovir + Placebo | Merck | Phase 3 | 40 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 43 |
| Enteric-coated mycophenolate sodium | Novartis | Phase 3 | 40 |
| Meningococcal C conjugate vaccine | Novartis | Approved | 43 |
| rMenB+OMV NZ | Novartis | Phase 3 | 40 |
| Enteric-Coated Mycophenolate Sodium | Novartis | Phase 3 | 40 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml | Novartis | Phase 3 | 44 |